CY2014039I2 - Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη - Google Patents

Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη

Info

Publication number: CY2014039I2
Authority: CY; Cyprus
Prior art keywords: pharmaceutical compositions; compositions containing; containing lurasidone; lurasidone; pharmaceutical
Prior art date: 2005-05-26

Application number

CY2014039C

Other languages

English (en)

Other versions

CY2014039I1 (el

Original Assignee

Sumitomo Dainippon Pharma Co., Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-26

Filing date

2014-09-18

Publication date

2016-06-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2014039(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-09-18 Application filed by Sumitomo Dainippon Pharma Co., Ltd. filed Critical Sumitomo Dainippon Pharma Co., Ltd.

2016-06-22 Publication of CY2014039I1 publication Critical patent/CY2014039I1/el

2016-06-22 Publication of CY2014039I2 publication Critical patent/CY2014039I2/el

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Psychiatry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CY2014039C 2005-05-26 2014-09-18 Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη CY2014039I2 (el)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2005153508		2005-05-26
PCT/JP2006/310571 WO2006126681A1 (ja)	2005-05-26	2006-05-26	医薬品組成物

Publications (2)

Publication Number	Publication Date
CY2014039I1 CY2014039I1 (el)	2016-06-22
CY2014039I2 true CY2014039I2 (el)	2016-06-22

Family

ID=37452103

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CY20131100384T CY1114118T1 (el)	2005-05-26	2013-05-14	Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη
CY2014039C CY2014039I2 (el)	2005-05-26	2014-09-18	Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY20131100384T CY1114118T1 (el)	2005-05-26	2013-05-14	Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη

Country Status (22)

Country	Link
US (5)	US8729085B2 (el)
EP (2)	EP1884242B1 (el)
JP (2)	JP4733120B2 (el)
KR (2)	KR101380088B1 (el)
CN (2)	CN102048734B (el)
AU (1)	AU2006250340C1 (el)
BE (1)	BE2014C057I2 (el)
BR (2)	BRPI0611409B8 (el)
CA (1)	CA2606510C (el)
CY (2)	CY1114118T1 (el)
DK (2)	DK2422783T3 (el)
ES (2)	ES2535478T3 (el)
FR (1)	FR14C0069I2 (el)
HU (1)	HUS1400051I1 (el)
LU (1)	LU92550I2 (el)
MX (1)	MX2007014872A (el)
NL (1)	NL300690I2 (el)
PL (1)	PL1884242T3 (el)
PT (1)	PT1884242E (el)
RU (1)	RU2398586C3 (el)
SI (1)	SI1884242T1 (el)
WO (1)	WO2006126681A1 (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2633088T3 (es) *	2005-05-18	2017-09-19	Sumitomo Dainippon Pharma Co., Ltd.	Comprimido estable que contiene droxidopa
DK2422783T3 (en) *	2005-05-26	2015-05-11	Sumitomo Dainippon Pharma Co Ltd	pharmaceutical composition
WO2009101940A1 (ja) *	2008-02-11	2009-08-20	Dainippon Sumitomo Pharma Co., Ltd.	溶出性の改善された錠剤
CN102119034B (zh)	2008-06-13	2013-05-22	大日本住友制药株式会社	在口腔中快速崩解的片剂和制备其的方法
JP5694773B2 (ja) *	2008-09-30	2015-04-01	テバ製薬株式会社	圧縮成型製剤およびその製造方法
EP3351240B1 (en)	2009-05-19	2019-04-10	Celgene Corporation	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
WO2012053654A1 (en)	2010-10-18	2012-04-26	Dainippon Sumitomo Pharma Co., Ltd.	Sustained-release formulation for injection
WO2012063246A1 (en) *	2010-11-11	2012-05-18	Mapi Pharma Ltd.	Amorphous form of lurasidone hydrochloride
WO2012107890A2 (en) *	2011-02-10	2012-08-16	Ranbaxy Laboratories Limited	Crystalline forms of lurasidone hydrochloride
US9433620B2 (en) *	2011-05-13	2016-09-06	Cadila Healthcare Limited	Pharmaceutical compositions of lurasidone
US8981095B2 (en)	2011-07-28	2015-03-17	Mapi Pharma Ltd.	Intermediate compounds and process for the preparation of lurasidone and salts thereof
CN102911169B (zh) *	2011-08-02	2015-05-06	上海医药工业研究院	一种卢拉西酮的制备方法
WO2013061338A1 (en)	2011-08-24	2013-05-02	Cadila Healthcare Limited	Pharmaceutical compositions of silodosin
CN103446071B (zh) *	2012-05-29	2017-12-19	江苏豪森药业集团有限公司	一种口服片剂及其制备方法和用途
CN102688209A (zh) *	2012-06-21	2012-09-26	李兴惠	鲁拉西酮片和制备方法
CN102688210A (zh) *	2012-06-21	2012-09-26	李兴惠	鲁拉西酮的药物组合物和制备方法
CN106074414B (zh) *	2012-07-12	2019-01-18	成都康弘药业集团股份有限公司	一种含有鲁拉西酮的口腔崩解片及其制备方法
CN103006661B (zh) *	2012-12-06	2015-02-18	江苏先声药物研究有限公司	一种含有盐酸鲁拉西酮的制剂及其制备方法
US20150157628A1 (en) *	2013-12-11	2015-06-11	Saravanan Kannusamy	Pharmaceutical compositions of Lurasidone and Process for preparation thereof
WO2016012898A1 (en)	2014-07-25	2016-01-28	Lupin Limited	Oral pharmaceutical composition of lurasidone
CN104606133A (zh) *	2015-01-07	2015-05-13	万特制药(海南)有限公司	鲁拉西酮口服混悬液及其制备方法
WO2016139683A2 (en) *	2015-03-05	2016-09-09	Jubilant Generics Limited	Pharmaceutical compositions of lurasidone and process for preparing the same
DE102016205950A1 (de) *	2016-04-08	2017-10-12	Dietrich Seidel	Mittel zur Verwendung bei entzündlichen Zuständen der Schleimhäute
EP3318279A1 (en) *	2016-11-02	2018-05-09	Sanovel Ilac Sanayi ve Ticaret A.S.	Solid oral pharmaceutical compositions of lurasidone hydrochloride
CN108567758A (zh) *	2017-03-08	2018-09-25	湖南洞庭药业股份有限公司	盐酸鲁拉西酮片剂及其制备方法
AU2018317472A1 (en) *	2017-08-18	2020-03-05	Abbvie Inc.	Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
CN107854445A (zh) *	2017-12-17	2018-03-30	佛山市弘泰药物研发有限公司	一种盐酸鲁拉西酮分散片及其制备方法
CN107875122A (zh) *	2017-12-17	2018-04-06	佛山市弘泰药物研发有限公司	一种盐酸鲁拉西酮自微乳制剂及其制备方法
CN107854446A (zh) *	2017-12-19	2018-03-30	佛山市弘泰药物研发有限公司	一种盐酸鲁拉西酮口崩片及其制备方法
WO2019167978A1 (ja)	2018-02-28	2019-09-06	大日本住友製薬株式会社	溶出が制御された水性懸濁型医薬製剤
PL3772992T3 (pl)	2018-04-10	2022-10-31	Freshfoodz Gmbh	Sposób konserwowania posiłku przygotowanego przez podgrzewanie i dostarczania żywienia zbiorowego
JP7585043B2 (ja) *	2018-04-13	2024-11-18	サムヤンホールディングスコーポレイション	レナリドミドを含む医薬組成物
EP4035733A4 (en) *	2019-09-25	2024-01-10	Nobelpharma Co., Ltd.	Granule having masked unpleasant taste and method for producing same
CN115843243B (zh) *	2020-08-26	2025-09-05	浙江华海药业股份有限公司	盐酸鲁拉西酮组合物及其制备方法
AT17300U3 (de) *	2020-12-03	2022-02-15	G L Pharma Gmbh	Feste orale pharmazeutische Zusammensetzung
MX2023007601A (es)	2020-12-23	2023-07-10	Sumitomo Pharma Co Ltd	Preparacion solida oral.

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4600579A (en) *	1983-06-07	1986-07-15	Mallinckrodt, Inc.	N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4551177A (en)	1984-04-23	1985-11-05	National Starch And Chemical Corporation	Compressible starches as binders for tablets or capsules
US4609675A (en)	1984-08-17	1986-09-02	The Upjohn Company	Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4837031A (en)	1987-09-17	1989-06-06	Mallinckrodt, Inc.	Compositions containing ibuprofen
US5047246A (en)	1988-09-09	1991-09-10	Bristol-Myers Company	Direct compression cyclophosphamide tablet
US4911921A (en)	1989-02-02	1990-03-27	Mallinckrodt, Inc.	High ibuprofen content granulations
US5104648A (en)	1989-02-02	1992-04-14	Mallinckrodt Specialty Chemicals Company	High ibuprofen content granulations
JP2800953B2 (ja)	1990-07-06	1998-09-21	住友製薬株式会社	新規なイミド誘導体
US5605889A (en)	1994-04-29	1997-02-25	Pfizer Inc.	Method of administering azithromycin
DE69624559T2 (de)	1995-02-28	2003-07-10	Aventis Pharmaceuticals Inc., Bridgewater	Arzneizubereitungen für piperidinalkanolderivate
JP4022269B2 (ja) *	1995-05-26	2007-12-12	協和醗酵工業株式会社	医薬組成物
ES2242298T3 (es)	1997-10-20	2005-11-01	Dainippon Pharmaceutical Co., Ltd.	Composicion medicamentos de disolucion rapida que contiene as-3201.
JP4063386B2 (ja) *	1998-01-29	2008-03-19	キッセイ薬品工業株式会社	速放性経口医薬品組成物
US6150366A (en)	1998-06-15	2000-11-21	Pfizer Inc.	Ziprasidone formulations
BR0009437A (pt) *	1999-03-31	2002-01-15	Janssen Pharmaceutica Nv	Amido pré-gelatinizado em uma formulação de liberação controlada
US6586617B1 (en)	1999-04-28	2003-07-01	Sumitomo Chemical Takeda Agro Company, Limited	Sulfonamide derivatives
WO2001076557A1 (en) *	2000-04-10	2001-10-18	Sumitomo Pharmaceuticals Co., Ltd.	Sustained release preparations
ES2325764T3 (es) *	2000-09-22	2009-09-16	Dainippon Sumitomo Pharma Co., Ltd.	Preparaciones orales con buenas caracteristicas de desintegracion.
ATE468325T1 (de)	2001-03-19	2010-06-15	Dainippon Sumitomo Pharma Co	Arylsubstituierte alicyclische verbindung und diese enthaltende medizinische zusammensetzung
GB0209265D0 (en)	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
DE60327634D1 (de) *	2002-08-22	2009-06-25	Dainippon Sumitomo Pharma Co	Mittel zur behandlung des integrationsdysfunktionssyndroms
CA2494707A1 (en)	2002-08-30	2005-01-06	Pharmacia Corporation	Pharmaceutical solid dosage forms exhibiting reproductible drug release profile
WO2004078173A1 (ja) *	2003-02-05	2004-09-16	Shionogi & Co., Ltd.	溶出性の改善された錠剤
DK3395340T3 (da)	2003-09-12	2019-07-15	Amgen Inc	Hurtigt opløsende formulering af cinacalcet-hcl
EP1695699A4 (en)	2003-12-09	2012-08-22	Dainippon Sumitomo Pharma Co	MEDICINAL GRAINS AND THE GRAINS CONTAINING SOLID PREPARATIONS
WO2006096439A2 (en)	2005-03-04	2006-09-14	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
DK2422783T3 (en)	2005-05-26	2015-05-11	Sumitomo Dainippon Pharma Co Ltd	pharmaceutical composition

2006
- 2006-05-26 DK DK11181100.6T patent/DK2422783T3/en active
- 2006-05-26 KR KR1020077027270A patent/KR101380088B1/ko active Active
- 2006-05-26 SI SI200631567T patent/SI1884242T1/sl unknown
- 2006-05-26 CA CA2606510A patent/CA2606510C/en active Active
- 2006-05-26 KR KR1020137027051A patent/KR101552033B1/ko active Active
- 2006-05-26 PL PL06746900T patent/PL1884242T3/pl unknown
- 2006-05-26 AU AU2006250340A patent/AU2006250340C1/en active Active
- 2006-05-26 WO PCT/JP2006/310571 patent/WO2006126681A1/ja not_active Ceased
- 2006-05-26 MX MX2007014872A patent/MX2007014872A/es active IP Right Grant
- 2006-05-26 BR BRPI0611409A patent/BRPI0611409B8/pt active IP Right Grant
- 2006-05-26 BR BR122020005056-0A patent/BR122020005056B1/pt active IP Right Grant
- 2006-05-26 CN CN2010105647842A patent/CN102048734B/zh not_active Expired - Fee Related
- 2006-05-26 EP EP06746900.7A patent/EP1884242B1/en active Active
- 2006-05-26 US US11/919,678 patent/US8729085B2/en active Active
- 2006-05-26 CN CN2006800182234A patent/CN101184489B/zh not_active Expired - Fee Related
- 2006-05-26 ES ES11181100.6T patent/ES2535478T3/es active Active
- 2006-05-26 ES ES06746900T patent/ES2408687T3/es active Active
- 2006-05-26 PT PT67469007T patent/PT1884242E/pt unknown
- 2006-05-26 DK DK06746900.7T patent/DK1884242T3/da active
- 2006-05-26 EP EP20110181100 patent/EP2422783B1/en active Active
- 2006-05-26 JP JP2007517921A patent/JP4733120B2/ja active Active
- 2006-05-26 RU RU2007148997A patent/RU2398586C3/ru not_active Application Discontinuation
2011
- 2011-03-18 JP JP2011061211A patent/JP5285105B2/ja active Active
2013
- 2013-05-14 CY CY20131100384T patent/CY1114118T1/el unknown
2014
- 2014-02-18 US US14/183,283 patent/US8883794B2/en active Active
- 2014-09-15 HU HUS1400051C patent/HUS1400051I1/hu unknown
- 2014-09-16 NL NL300690C patent/NL300690I2/nl unknown
- 2014-09-16 FR FR14C0069C patent/FR14C0069I2/fr active Active
- 2014-09-17 BE BE2014C057C patent/BE2014C057I2/fr unknown
- 2014-09-18 CY CY2014039C patent/CY2014039I2/el unknown
- 2014-09-18 LU LU92550C patent/LU92550I2/xx unknown
- 2014-10-10 US US14/512,189 patent/US9555027B2/en active Active
2015
- 2015-06-08 US US14/733,204 patent/US9907794B2/en active Active
2018
- 2018-02-06 US US15/889,893 patent/US20180161322A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2006250340C1 (en)	2014-06-12
BRPI0611409A8 (pt)	2015-12-15
ES2535478T3 (es)	2015-05-12
FR14C0069I2 (fr)	2015-11-20
FR14C0069I1 (fr)	2014-10-24
US20140235651A1 (en)	2014-08-21
PL1884242T3 (pl)	2013-09-30
LU92550I2 (fr)	2015-11-02
US8883794B2 (en)	2014-11-11
BRPI0611409A2 (pt)	2010-11-23
CA2606510C (en)	2014-07-22
JP2011126915A (ja)	2011-06-30
SI1884242T1 (sl)	2013-07-31
RU2398586C2 (ru)	2010-09-10
BR122020005056A8 (pt)	2022-11-22
EP1884242A4 (en)	2009-07-01
EP1884242B1 (en)	2013-04-17
CN102048734A (zh)	2011-05-11
US9555027B2 (en)	2017-01-31
KR20080012306A (ko)	2008-02-11
US8729085B2 (en)	2014-05-20
DK2422783T3 (en)	2015-05-11
CN101184489A (zh)	2008-05-21
AU2006250340A1 (en)	2006-11-30
RU2007148997A (ru)	2009-07-10
WO2006126681A1 (ja)	2006-11-30
US20180161322A1 (en)	2018-06-14
JP4733120B2 (ja)	2011-07-27
KR20130122019A (ko)	2013-11-06
US20090143404A1 (en)	2009-06-04
BRPI0611409B1 (pt)	2020-12-29
KR101380088B1 (ko)	2014-04-10
CA2606510A1 (en)	2006-11-30
ES2408687T3 (es)	2013-06-21
BR122020005056B1 (pt)	2023-01-10
NL300690I2 (nl)	2017-11-02
MX2007014872A (es)	2008-02-15
US20150056284A1 (en)	2015-02-26
DK1884242T3 (da)	2013-05-06
BR122020005056A2 (el)	2010-11-23
AU2006250340B2 (en)	2012-02-09
HUS1400051I1 (hu)	2016-10-28
CY1114118T1 (el)	2016-06-22
HK1108379A1 (en)	2008-05-09
BE2014C057I2 (el)	2025-12-10
JP5285105B2 (ja)	2013-09-11
EP2422783B1 (en)	2015-04-08
CN101184489B (zh)	2011-01-19
US20150265611A1 (en)	2015-09-24
CY2014039I1 (el)	2016-06-22
PT1884242E (pt)	2013-05-21
JPWO2006126681A1 (ja)	2008-12-25
CN102048734B (zh)	2013-11-20
BRPI0611409B8 (pt)	2021-05-25
RU2398586C3 (ru)	2017-10-04
EP2422783A1 (en)	2012-02-29
EP1884242A1 (en)	2008-02-06
KR101552033B1 (ko)	2015-09-09
US9907794B2 (en)	2018-03-06

Publication	Publication Date	Title
CY2014039I2 (el)	2016-06-22	Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη
BRPI0511900A (pt)	2008-01-22	composições farmacêuticas
ITBO20050123A1 (it)	2005-06-06	Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
BRPI0715712A2 (pt)	2014-06-24	Composição farmacêutica
DK1962873T3 (da)	2013-08-26	Farmaceutiske sammensætninger omfattende oxalat-reducerende bakterier
NO20075628L (no)	2007-11-05	Farmasøytiske formuleringer
BRPI0719393A2 (pt)	2015-03-31	Composição farmacêutica
BRPI0613033A2 (pt)	2016-11-29	composição oral
BRPI0810928A2 (pt)	2019-09-24	"composição farmacêutica"
DK1940467T3 (da)	2017-02-13	Lægemiddelsammensætning med langvarig frigivelse
DK2966175T3 (da)	2019-07-01	Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
BRPI0716445A2 (pt)	2013-09-17	composiÇço farmacÊutica
BRPI0720234A2 (pt)	2013-12-24	Composição farmacêutica
NO20055686D0 (no)	2005-12-01	Sammensetning
DK1725218T3 (da)	2014-09-01	Farmaceutisk sammensætning omfattende pimobendan
IL187748A0 (en)	2008-04-13	Pharmaceutical compositions containing misoprostal
DK1957073T3 (da)	2014-05-12	Lægemiddel
ATE414501T1 (de)	2008-12-15	Antiperspirant-zusammensetzungen
DE502006006590D1 (de)	2010-05-12	Biozide zusammensetzungen
EP1937255A4 (en)	2013-06-26	PHARMACEUTICAL COMPOSITION
ATE515256T1 (de)	2011-07-15	Antiperspirans-zusammensetzungen
EP1862184A4 (en)	2012-12-19	PHARMACEUTICAL COMPOSITION
ATE452628T1 (de)	2010-01-15	Anthelminthische zusammensetzung
ITMI20041447A1 (it)	2004-10-20	Composizione farmaceutica comprendente gabapentina
NO20050614L (no)	2006-08-04	Refractory compositions